Tillkännagivande • Mar 28
China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 51.46211 million. China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 51.46211 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 205,848,440
Price\Range: HKD 0.25
Transaction Features: Rights Offering Tillkännagivande • Feb 12
China Health Technology Group Holding Company Limited to Report First Half, 2026 Results on Feb 27, 2026 China Health Technology Group Holding Company Limited announced that they will report first half, 2026 results on Feb 27, 2026 Tillkännagivande • Dec 10
China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 31, 2025 China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 31, 2025, at 11:00 China Standard Time. Location: unit no. 2808-10, 28th floor of west tower shun tak centre, nos. 168-200 connaught road central, Hong Kong Tillkännagivande • Sep 18
China Health Technology Group Holding Company Limited to Report Fiscal Year 2025 Results on Sep 30, 2025 China Health Technology Group Holding Company Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Sep 30, 2025 Tillkännagivande • Aug 01
China Health Technology Group Holding Company Limited has completed a Follow-on Equity Offering in the amount of HKD 4.76 million. China Health Technology Group Holding Company Limited has completed a Follow-on Equity Offering in the amount of HKD 4.76 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 17,000,000
Price\Range: HKD 0.28
Discount Per Security: HKD 0.0042
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jul 22
China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 4.76 million. China Health Technology Group Holding Company Limited has filed a Follow-on Equity Offering in the amount of HKD 4.76 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 17,000,000
Price\Range: HKD 0.28
Discount Per Security: HKD 0.0042
Transaction Features: Subsequent Direct Listing Tillkännagivande • Mar 14
China Health Technology Group Holding Company Limited Announces Appointment of Li Zhiliang as Chief Executive Officer of Subsidiary, Genmao (Shenzhen) Biotechnology Co., Ltd China Health Technology Group Holding Company Limited board of directors announced that Mr. Li Zhiliang ("Mr. Li") has been appointed as the chief executive officer of Genmao (Shenzhen) Biotechnology Co. Ltd. ("Genmao Biotech"), a wholly-owned subsidiary of the Company, responsible for the strategic planning, business expansion, and daily operational management of the company with effect from 12 March 2025. Mr. Li is a senior expert in the acer truncatum industry. He has been engaged in the entire industrial chain of acer truncatum for 22 years and has rich management experience. Mr. Li has been deeply involved in the formulation of the National Standard for Acer Truncatum Bunge Seed Oil (GB/T37748-2019) and has participated in the implementation of various national-level acer truncatum industry integration projects. The Board believes that Mr. Li's professional qualifications, industry resources and management capabilities are highly consistent with Genmao Biotech's strategic direction of focusing on the development of the entire industrial chain of acer truncatum. Such appointment will significantly enhance the Company's technological barriers and brand influence in the functional food and oil market, creating long-term value for shareholders. Tillkännagivande • Feb 18
China Health Technology Group Holding Company Limited to Report First Half, 2025 Results on Feb 28, 2025 China Health Technology Group Holding Company Limited announced that they will report first half, 2025 results on Feb 28, 2025 Tillkännagivande • Dec 05
China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 30, 2024 China Health Technology Group Holding Company Limited, Annual General Meeting, Dec 30, 2024, at 15:30 China Standard Time. Location: unit no. 2808-10 on 28th floor, west tower shun tak centre, nos. 168-200 connaught road central, Hong Kong Tillkännagivande • Sep 17
China Health Technology Group Holding Company Limited to Report Fiscal Year 2024 Results on Sep 30, 2024 China Health Technology Group Holding Company Limited announced that they will report fiscal year 2024 results at 9:30 AM, China Standard Time on Sep 30, 2024 Tillkännagivande • Feb 20
China Health Technology Group Holding Company Limited to Report Second Half, 2023 Results on Feb 29, 2024 China Health Technology Group Holding Company Limited announced that they will report second half, 2023 results on Feb 29, 2024 Tillkännagivande • Feb 01
China Health Technology Group Holding Company Limited Announces Executive Changes The board of directors of China Health Technology Group Holding Company Limited announced that Mr. Ngai Tsz Hin Michael ("Mr. Ngai") has tendered his resignation as the joint company secretary of the Company (the "Company Secretary") and ceased to act as an authorised representative of the Company (the "Authorised Representative") under Rule 3.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") with effect from 31 January 2024. The Board also announced that, following the resignation of Mr. Ngai, Mr. Chan Ngai Fan ("Mr. Chan"), the existing company secretary of the Company, will continue to act as the Company Secretary and Mr. Chan has been appointed as the Authorised Representative with effect from 31 January 2024. Following the change, the Authorised Representatives are Professor Fei Phillip and Mr. Chan. Tillkännagivande • Jan 30
China Health Technology Group Holding Company Limited Announces Resignation of Chan Wai Lung as an Executive Director China Health Technology Group Holding Company Limited announced that Mr. Chan Wai Lung has resigned as an executive Director with effect from 29 January 2024 due to his other business engagements requiring more of time. Tillkännagivande • Oct 31
China Bozza Development Holdings Limited, Annual General Meeting, Nov 21, 2023 China Bozza Development Holdings Limited, Annual General Meeting, Nov 21, 2023, at 15:30 China Standard Time. Location: Unit No. 280810 on 28th Floor of West Tower Shun Tak Centre Nos. 168200 Connaught Road Central, Hong Kong Hong Kong Agenda: To receive, consider and adopt the audited financial statements, the report of the directors (the "Directors") and the report of the independent auditor for the eighteen months ended 30 June 2021; to receive, consider and adopt the audited financial statements, the report of the Directors and the report of the independent auditor for the year ended 30 June 2022; to receive, consider and adopt the audited financial statements, the report of the Directors and the report of the independent auditor for the year ended 30 June 2023; and to consider other matters. Tillkännagivande • Sep 22
China Bozza Development Holdings Limited to Report Fiscal Year 2023 Results on Sep 30, 2023 China Bozza Development Holdings Limited announced that they will report fiscal year 2023 results on Sep 30, 2023 Tillkännagivande • Sep 09
China Bozza Development Holdings Limited (SEHK:1069) entered into equity sale and purchase agreement to acquire 52% stake in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development Company Limited from Shaanxi Jiashisen Pharmaceutical Investment Company Limited for CNY 7.1 million. China Bozza Development Holdings Limited (SEHK:1069) entered into equity sale and purchase agreement to acquire 52% stake in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development Company Limited from Shaanxi Jiashisen Pharmaceutical Investment Company Limited for CNY 7.1 million on August 16, 2023. Upon the Completion, China Bozza Development will hold 52% equity interest in Liuba County Jiashisen Traditional Chinese Medicine Comprehensive Development, which will become a non-wholly owned subsidiary of the China Bozza Development. Tillkännagivande • Aug 17
China Bozza Development Holdings Limited Announces Board Changes The board (the "Board") of directors (the "Director(s)") of China Bozza Development Holdings Limited (the "Company", and together with its subsidiaries, the "Group") announced that Mr. Chan Wai Lung ("Mr. Chan"), an independent non-executive Director, has been re-designated as an executive Director with effect from 14 August 2023. Mr. Chan Wai Lung, aged 42, was appointed as an independent non-executive Director on 19 May 2023. Mr. Chan has years of experience in business planning and development. Mr. Chan has been an executive Director of Finsoft Financial Investment Holdings Limited since June 2017 and has been the Chief Executive Officer of Finsoft since December 2021. Mr. Chan has been a director of Draco International Investment (Holdings) Limited (specialising in designing corporate structures) since July 2013, and a director of Draco Human Resources Management Limited since November 2016. Mr. Chan was a non-executive director of Noble Engineering Group Holdings Limited, from August 2018 to January 2020. Mr. Chan was appointed as a business development consultant by the Management Committee of the Haining Economic Development Zone, Zhejiang Province, the PRC in April 2017. In October 2017, he obtained his Honorary Doctorate in Business Administration from Sabi University. In November 2019, Mr. Chan completed a postdoctoral research project at California State University Monterey Bay. The Board also announced that (i) Mr. Chau Wing Nam ("Mr. Chau") has been appointed as an independent non-executive Director, the chairman of the audit committee of the Company (the "Audit Committee") and the chairman of the Remuneration Committee; and (ii) Ms. Bu Xue has been appointed as an independent non-executive Director and a member of each of the Audit Committee, the Remuneration Committee and the nomination committee of the Company (the "Nomination Committee") with effect from 14 August 2023. Mr. Chau Wing Nam, aged 35, obtained his Bachelor's degree in Accounting and Accounting Technologies from the Curtin University of Technology in August 2012. He has been a member of Hong Kong Institute of Certified Public Accountants since May 2017. He has over ten years of experience in auditing, accounting and corporate management and is currently responsible for corporate finance, mergers and acquisitions matters, investors relations, corporate governance as well as compliance affairs. Mr. Chau is currently a manager of Ample Capital Limited and is a licensed person registered under the Securities and Futures Ordinance to carry out Type 6 (advising on corporate finance) regulated activity. Mr. Chau is currently an independent non-executive director of K Group Holdings Limited since June 2022 and an independent non-executive director of Mobile Internet (China) Holdings Limited since February 2023. Ms. Bu Xue, aged 34, obtained her Bachelor's degree in Business Administration from Zhengzhou University of Aeronautics in July 2011. She has attained the accounting professional qualification issued by Ministry of Human Resources and Social Security and Ministry of Finance of the People's Republic of China since September 2020 and has attained the qualification of tax advisor issued by The China Certified Tax Agents Association since December 2022. She has over ten years of experience in marketing and business development. The Board also announced that, following the change in the composition of the Board and with effect from 14 August 2023: Mr. Liu Zhaoxiang ceased to be a member of the Audit Committee; Ms. Wong Hoi Ying ceased to be the chairman of the Nomination Committee and a member of each of the Audit Committee and the Remuneration Committee; Professor Fei Phillip ceased to be a member of each of the Remuneration Committee and Nomination Committee; Mr. Wang Yibin has been appointed as a member of the Nomination Committee; Mr. Guo Zhonglong has been appointed as the chairman of the Nomination Committee and a member of the Remuneration Committee and has been re-designated as a member of the Audit Committee; Mr. Chan ceased to be the chairman of the Remuneration Committee and a member of each of the Audit Committee and Nomination Committee; Mr. Chau has been appointed as the chairman of the Audit Committee and the chairman of the Remuneration Committee; and Ms. Bu has been appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee. 
